{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T05:57:23Z","timestamp":1790575043129,"version":"4.1.0"},"reference-count":26,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T00:00:00Z","timestamp":1790553600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100015391","name":"Myositis Association","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015391","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Myositis-specific autoantibodies (MSAs) are clinically important biomarkers that help classify idiopathic inflammatory myopathies and guide clinical management, but reliable detection remains challenging. Immunoprecipitation (IP) is widely regarded as a reference method for MSA detection in specialist laboratories. However, IP comprises a range of related techniques rather than a single standardised assay, and variability between expert laboratories using different IP-based workflows is not well characterised.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Serum samples previously submitted to the Bath Diagnostic Serology Service were distributed to three collaborating reference laboratories. Centres analysed samples using their routine workflows, which included radiolabelled protein IP, RNA-IP, IP-western blotting, IP-mass spectrometry, and supplementary immunoassays. Results were interpreted within each laboratory's diagnostic framework, and interlaboratory concordance of MSA detection and specificity assignment was evaluated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Thirty-two samples were included. Overall concordance across overlap groups ranged from 63\u201378%. Agreement varied by MSA specificity and methodological scope. Anti-Zo, anti-NXP2 and anti-TIF1\u03b3 demonstrated the highest reproducibility, whereas anti-PL-7, anti-Jo-1, anti-EJ, anti-Ha and anti-HMGCR were identified only by isolated laboratories. Differences were consistent with variation in IP method, including antigen source, detection modality and availability of reference sera. Complementary assays played an essential role in anti-MDA5, anti-HMGCR and anti-NXP2 antibody detection.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>These findings demonstrate that IP-based testing should be considered a framework of expert diagnostic practice rather than a single uniform assay. Greater transparency in laboratory methods and reporting practices may improve interpretation of autoantibody results and support more consistent comparison of MSA results across clinical and research settings.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1918595","type":"journal-article","created":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T05:45:33Z","timestamp":1790574333000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Interlaboratory comparison of immunoprecipitation-based testing for myositis-specific autoantibodies"],"prefix":"10.3389","volume":"17","author":[{"given":"Kimberly","family":"Loh","sequence":"first","affiliation":[{"name":"Department of Life Sciences, University of Bath","place":["Bath, United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgina R","family":"Harvey","sequence":"additional","affiliation":[{"name":"Department of Life Sciences, University of Bath","place":["Bath, United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Bossuyt","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, University Hospitals Leuven, Leuven, Belgium and Department of Microbiology, Immunology and Transplantation, KU Leuven","place":["Leuven, Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Brusch","sequence":"additional","affiliation":[{"name":"Department of Clinical Immunology, PathWest Laboratory Medicine","place":["Perth, WA, Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chris","family":"Bundell","sequence":"additional","affiliation":[{"name":"Department of Clinical Immunology, PathWest Laboratory Medicine","place":["Perth, WA, Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei","family":"Cheng","sequence":"additional","affiliation":[{"name":"Arthritis & Clinical Immunology Research Program, Oklahoma Medical Research Foundation","place":["Oklahoma City, OK, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masataka","family":"Kuwana","sequence":"additional","affiliation":[{"name":"Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine","place":["Tokyo, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Lu","sequence":"additional","affiliation":[{"name":"Department of Life Sciences, University of Bath","place":["Bath, United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Birthe","family":"Michiels","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, University Hospitals Leuven, Leuven, Belgium and Department of Microbiology, Immunology and Transplantation, KU Leuven","place":["Leuven, Belgium"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan","family":"Ronnelid","sequence":"additional","affiliation":[{"name":"Department of Immunology, Genetics and Pathology, Uppsala Universitet","place":["Uppsala, Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ira N","family":"Targoff","sequence":"additional","affiliation":[{"name":"Arthritis & Clinical Immunology Research Program, Oklahoma Medical Research Foundation","place":["Oklahoma City, OK, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akira","family":"Yoshida","sequence":"additional","affiliation":[{"name":"Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine","place":["Tokyo, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil J","family":"McHugh","sequence":"additional","affiliation":[{"name":"Department of Life Sciences, University of Bath","place":["Bath, United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah L","family":"Tansley","sequence":"additional","affiliation":[{"name":"Department of Life Sciences, University of Bath","place":["Bath, United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,28]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1038\/s41572-021-00321-x","article-title":"Idiopathic inflammatory myopathies","volume":"7","author":"Lundberg","year":"2021","journal-title":"Nat Rev Dis Primers"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/s1474-4422(18)30254-0","article-title":"Classification and management of adult inflammatory myopathies","volume":"17","author":"Selva-O'Callaghan","year":"2018","journal-title":"Lancet Neurol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.jaut.2019.04.001","article-title":"Frequency, mutual exclusivity and clinical associations of myositis autoantibodies in a combined European cohort of idiopathic inflammatory myopathy patients","volume":"101","author":"Betteridge","year":"2019","journal-title":"J Autoimmun"},{"key":"B4","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.jaut.2017.06.007","article-title":"Autoantibodies in juvenile-onset myositis: Their diagnostic value and associated clinical phenotype in a large UK cohort","volume":"84","author":"Tansley","year":"2017","journal-title":"J Autoimmun"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-023-06719-0","article-title":"Association between self-reported race and ethnicity and myositis-specific autoantibodies in a diverse cohort of patients with inflammatory myopathy","volume":"42","author":"Beam","year":"2023","journal-title":"Clin Rheumatol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1674437","article-title":"Association of clinical features and myositis-specific antibodies in idiopathic inflammatory myopathy: a retrospective study from southern China","volume":"16","author":"Li","year":"2025","journal-title":"Front Immunol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12016-015-8510-y","article-title":"A comprehensive overview on myositis-specific antibodies: New and old biomarkers in idiopathic inflammatory myopathy","volume":"52","author":"Satoh","year":"2017","journal-title":"Clin Rev Allergy Immunol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s11926-024-01171-8","article-title":"Newer autoantibodies and laboratory assessments in myositis","volume":"27","author":"Harvey","year":"2024","journal-title":"Curr Rheumatol Rep"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keaa021","article-title":"The reliability of immunoassays to detect autoantibodies in patients with myositis is dependent on autoantibody specificity","volume":"59","author":"Tansley","year":"2020","journal-title":"Rheumatology"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kem045","article-title":"Anti-synthetase syndrome: a new autoantibody to phenylalanyl transfer RNA synthetase (anti-Zo) associated with polymyositis and interstitial pneumonia","volume":"46","author":"Betteridge","year":"2007","journal-title":"Rheumatology"},{"key":"B11","doi-asserted-by":"publisher","first-page":"291","DOI":"10.21037\/atm-21-475","article-title":"Narrative review of autoantibodies in idiopathic inflammatory myopathies","volume":"11","author":"Liu","year":"2023","journal-title":"Ann Transl Med"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics14192192","article-title":"Comparison of lineblot and immunoprecipitation methods in the detection of myositis-specific and myositis-associated antibodies in patients with idiopathic inflammatory myopathies: consistency with clinical diagnoses","volume":"14","author":"Angeli","year":"2024","journal-title":"Diagnostics (Basel)"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keae167","article-title":"Assessing the sensitivity and specificity of myositis-specific and associated autoantibodies: a sub-study from the MyoCite cohort","volume":"63","author":"Loganathan","year":"2024","journal-title":"Rheumatology"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2025.152858","article-title":"Analytical performance of commercial myositis-specific autoantibody tests evaluated against immunoprecipitation assays as a reference standard: A systematic review and meta-analysis","volume":"75","author":"Gono","year":"2025","journal-title":"Semin Arthritis Rheum"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1093\/mr\/roag003","article-title":"Development of enzyme-linked immunosorbent assays for the detection of myositis-specific autoantibodies against signal recognition particle, nuclear matrix protein 2, and small ubiquitin-like modifier activating enzyme","volume":"36","author":"Murakami","year":"2026","journal-title":"Modern Rheumatol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1093\/mr\/roac056","article-title":"A multianalyte assay for the detection of dermatomyositis-related autoantibodies based on immunoprecipitation combined with immunoblotting","volume":"33","author":"Kuwana","year":"2022","journal-title":"Modern Rheumatol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-222686","article-title":"Mass spectrometry-based identification of new anti-Ly and known antisynthetase autoantibodies","volume":"82","author":"Vulsteke","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.ard.2025.05.008","article-title":"The TFIID complex is a new autoantibody target in systemic sclerosis","volume":"85","author":"Vulsteke","year":"2026","journal-title":"Ann Rheum Dis"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1002\/art.27572","article-title":"A novel autoantibody recognizing 200-kd and 100-kd proteins is associated with an immune-mediated necrotizing myopathy","volume":"62","author":"Christopher-Stine","year":"2010","journal-title":"Arthritis Rheum"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1002\/art.30156","article-title":"Autoantibodies against 3-hydroxy-3-methylglutaryl-coenzyme A reductase in patients with statin-associated autoimmune myopathy","volume":"63","author":"Mammen","year":"2011","journal-title":"Arthritis Rheum"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a041253","article-title":"Post-translational regulation of HMG CoA reductase","volume":"14","author":"Jo","year":"2022","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.m201440200","article-title":"The newly identified human nuclear protein NXP-2 possesses three distinct domains, the nuclear matrix-binding, RNA-binding, and coiled-coil domains","volume":"277","author":"Kimura","year":"2002","journal-title":"J Biol Chem"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1242\/jcs.063586","article-title":"Two-step colocalization of MORC3 with PML nuclear bodies","volume":"123","author":"Mimura","year":"2010","journal-title":"J Cell Sci"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.022637199","article-title":"mda-5: An interferon-inducible putative RNA helicase with double-stranded RNA-dependent ATPase activity and melanoma growth-suppressive properties","volume":"99","author":"Kang","year":"2002","journal-title":"Proc Natl Acad Sci USA"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1212186109","article-title":"MDA5 assembles into a polar helical filament on dsRNA","volume":"109","author":"Berke","year":"2012","journal-title":"Proc Natl Acad Sci USA"},{"key":"B26","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.1016\/j.molcel.2024.05.004","article-title":"hnRNPM protects against the dsRNA-mediated interferon response by repressing LINE-associated cryptic splicing","volume":"84","author":"Zheng","year":"2024","journal-title":"Mol Cell"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1918595\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T05:45:34Z","timestamp":1790574334000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1918595\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,28]]},"references-count":26,"alternative-id":["10.3389\/fimmu.2026.1918595"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1918595","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,28]]},"article-number":"1918595"}}